SCI时时刷

search
+
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Cleara...
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
We read the interesting epidemiological study on 600 patients with rheumatic diseases hospitalised for COVID-19 infection ...
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies
WHAT IS ALREADY KNOWN ON THIS TOPICComplement activation causes damage to the skin and muscles in myositis through the for...
Response to: 'Correspondence on 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management by Snarskaya and Vasileva
Response to: 'Correspondence on 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management by Snarskaya and Vasileva
We read with great interest the response from Snarskaya and Vasileva.1 A second wave of SARS-CoV-2 infection is now a glob...
PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
ResultsPU.1 and FMS-like tyrosine kinase 3 expression in RA patientsTo investigate the specific role of PU.1 in RA, we fir...
Correspondence on 'Systemic sclerosis and the COVID-19 pandemic--World Scleroderma Foundation preliminary advice for patient management
Correspondence on 'Systemic sclerosis and the COVID-19 pandemic--World Scleroderma Foundation preliminary advice for patient management
The actual question is raised in this article whether it is worth continuing the immunosuppressive treatment in patients w...
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
AbstractObjectives To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VT...
Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey
Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey
COVID-19, caused by the SARS-CoV-2, is an unprecedented global pandemic. Advanced age and cardiovascular diseases are reco...
Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey by Comarmond et al
Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey by Comarmond et al
We read with interest the correspondence by Comarmond et al 1 on our study about the impact of novel COVID-19 on Italian p...
Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
We read with a great interest the comment from Ciurea et al 1 recently published in Annals of Rheumatic Diseases about the...
Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
We read with great interest the paper of Ramiro et al 1 comparing the effectiveness of glucocorticoids (GC) treatment alon...
Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort by Ruyssen-Witrand et al
Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort by Ruyssen-Witrand et al
We would like to thank Ruyssen-Witrand et al for their interest in our study1 and their data from French patients with rhe...
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
WHAT IS ALREADY KNOWN ON THIS TOPICChildren of women with systemic lupus erythematosus (SLE) have a higher risk of birth d...
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study by Calvo-Aranda et al
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study by Calvo-Aranda et al
We read with interest the letter from Calvo-Aranda et al 1 on our COVID high-intensity immunosuppression in cytokine storm...
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
WHAT IS ALREADY KNOWN ON THIS TOPICHumoral immune response after COVID-19 vaccination can be impaired in patients with imm...
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Cleara...
Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis
Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis
Floudas A, Neto N, Orr C, et al. Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfuncti...
Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis by Sun and Ni
Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis by Sun and Ni
We read with great interest the letter by Sun and Ni.1 Our study described an increased relative abundance in Prevotella s...
Clinical trials in systemic lupus erythematosus: the dilemma--Why have phase III trials failed to confirm the promising results of phase II trials?
Clinical trials in systemic lupus erythematosus: the dilemma--Why have phase III trials failed to confirm the promising results of phase II trials?
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of unknown aetiology, characterised by the productio...
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
An analysis of the Janus kinases (JAK)-pot collaboration of registries, recently reported on the comparative effectiveness...
Response to: 'Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis by Garcia et al
We appreciate the interest of García and Abud-Mendoza in our article on tapering towards disease-modifying antirheumatic d...
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Video Abstract Disclaimer: this video summarises a scientific article published by BMJ Publishing Group Limited (BMJ). The...
Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis
We believe that the article ‘Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of ...
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
IntroductionDisease activity in rheumatoid arthritis (RA) was initially defined by a number of core set variables, agreed ...
Response to: 'Correspondence on 'Gender disparity in authorship of guidelines and recommendations in rheumatology by Stewart et al
We thank Stewart et al for their positive comments on our work and we applaud to their effort in refining and extending ou...
2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work
IntroductionIn nearly all European countries, the work participation gap between people with chronic diseases, especially ...
Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases by Schulze-Koops et al
We appreciate the interest of Dr Schulze-Koops and colleagues in our article.1 The role of the inflammatory rheumatic dise...
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
The task force’s deliberations resulted in 11 recommendations, 1 less than in 20195 and 4 less than in the first version i...
Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study
Tocilizumab (TCZ), a recombinant monoclonal antibody against the interleukin (IL)-6 receptor, has been proposed as a poten...
Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
We read with great interest the meta-analysis by Akiyama et al showing that out of 62 studies with over 300 000 patients w...
阅读更多
format_indent_increase